FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Male hormones regulate stomach inflammation in mice
NIEHS research shows that male sex hormones are anti-inflammatory and could lead to new treatment strategies for stomach cancer. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - June 2, 2021 Category: Environmental Health Source Type: news

Liver, Gastric Cancer Disparities Consistent Across Race Liver, Gastric Cancer Disparities Consistent Across Race
A recent analysis of US data clearly highlights the need to step up efforts to help level disparities in gastrointestinal cancer.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Male hormones regulate stomach inflammation in mice
NIH research could lead to new treatment strategies for stomach cancer. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 14, 2021 Category: American Health Source Type: news

Male hormones regulate stomach inflammation in mice
(NIH/National Institute of Environmental Health Sciences) Scientists at the National Institutes of Health determined that stomach inflammation is regulated differently in male and female mice after finding that androgens, or male sex hormones, play a critical role in preventing inflammation in the stomach. The finding suggests that physicians could consider treating male patients with stomach inflammation differently than female patients with the same condition. The study was published in Gastroenterology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2021 Category: Cancer & Oncology Source Type: news

Cancer may cause stomach bloating if the tumour is growing in size
CANCER statistics are shocking - one in two people will develop the disease at some point during their lifetime. Thankfully, advances in treatment has increased survival chances by more than half. However, early diagnosis is vital. (Source: Daily Express - Health)
Source: Daily Express - Health - May 13, 2021 Category: Consumer Health News Source Type: news

All gas, no brakes: Testosterone may act as 'brake pedal' on immune response
(West Virginia University) Jonathan Busada, a researcher with the WVU School of Medicine and Cancer Institute, has investigated the role that hormones play in male and female inflammatory responses. In a new study, he found that testosterone may protect against stomach inflammation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 12, 2021 Category: Cancer & Oncology Source Type: news

FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
VANCOUVER, BC, May 11, 2021 -- (Healthcare Sales & Marketing Network) -- Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in t... Biopharmaceuticals, Oncology, FDA Bold Therapeutics, BOLD-100, ruthenium, Gastric Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 11, 2021 Category: Pharmaceuticals Source Type: news

Stomach bloating may be a tell-tale symptom of a tumour in the reproductive organs
STOMACH bloating that is persistent is one key sign of ovarian cancer; there are three other signs, including urinary symptoms. What toiletry habits should you be taking note of? (Source: Daily Express - Health)
Source: Daily Express - Health - May 7, 2021 Category: Consumer Health News Source Type: news

FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news

Gastrectomy for Gastric Cancer Associated With Weight Loss, Diabetes Remission Gastrectomy for Gastric Cancer Associated With Weight Loss, Diabetes Remission
Gastric cancer patients with diabetes who undergo conventional gastrectomy have an increased likelihood of diabetes remission with greater postoperative weight loss, independent of baseline weight, a recent study suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 4, 2021 Category: Surgery Tags: General Surgery News Source Type: news

Mortality Risk Up for Fragmented Care After Complex Cancer Surgery
Mortality higher for patients readmitted to outside hospital rather than index hospital after hepatopancreatobiliary or gastric cancer surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Mortality Risk Up for Fragmented Care After Complex Cancer Surgery
MONDAY, May 3, 2021 -- Travel distance and timing contribute to care fragmentation following hepatopancreatobiliary (HPB) and gastric oncologic operations, according to a study published online April 15 in the Journal of the American College of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news

Humana partially reverses PET/CT policy
Humana will begin covering PET/CT imaging for gastric and esophageal oncologi...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT may increase survival in SCC patients FDG-PET/CT effective for staging in new breast cancer SNMMI provides update on COVID-19 vaccine and PET/CT PET/CT shows link between stress and fatal heart condition Nuclear medicine groups oppose Humana PET/CT policy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 27, 2021 Category: Radiology Source Type: news

Cholestenone shows antibiotic properties against H. pylori
(Shinshu University) Helicobacter pylori, a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and gastric malignant lymphoma. It can be eradicated in most infected people using a combination of three drugs including antibiotics clarithromycin. However drug-resistant H. Pylori is a growing problem and it is expected to develop drugs that exhibit anti-H. pylori activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2021 Category: International Medicine & Public Health Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
FDA granted Opdivo first approval of immunotherapy for first - line treatment of advanced or metastatic gastric cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, FDA Approvals, Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
TUESDAY, April 20, 2021 -- Opdivo (nivolumab) is now approved for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the U.S. Food and Drug Administration announced Friday. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 20, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Frontline Immunotherapy for Gastric Cancers FDA Approves Frontline Immunotherapy for Gastric Cancers
The approval marked a first for an immunotherapy in patients with gastric cancers.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Potential ways to improve survival for cancer patients who receive fragmented care
(American College of Surgeons) New research reveals that 28 percent of patients who are readmitted to the hospital with complications after surgical removal of pancreatic, liver, or stomach cancer go to a different hospital for follow-up care. This fragmentation of health care is associated with a 50 percent increased odds of dying, according to a study published online by the Journal of the American College of Surgeons ahead of print. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

Predicting Gastric Cancer Risk After H. Pylori Eradication Predicting Gastric Cancer Risk After H. Pylori Eradication
This study evaluated the performance of seven different machine learning models in predicting gastric cancer risk after H. pylori eradication. Which was most accurate?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

A tummy invader: This bacterial molecule may be key to fighting stomach cancer
(Osaka University) Researchers from Osaka University found thatH. pylori bacterial strains with low expression of a small RNA molecule called HPnc4160 are more likely to adapt to living in the human stomach. Gastric cancer patients have lower levels of HPnc4160, as well as higher levels of pathogenic bacterial proteins, than individuals without cancer. This work provides crucial knowledge for the development of new treatments for chronicH. pylori infections and gastric cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

Lycopene found to inhibit pathway involved in Helicobacter pylori-induced gastric cancer
In this study, researchers at Yonsei University in South Korea evaluated the effects of lycopene on hyperproliferation induced by Helicobacter pylori infection. They reported their findings in an article published in the journal Nutrition Research. H. pylori is known to colonize the human stomach and is linked to an increased risk of gastric diseases,... (Source: NaturalNews.com)
Source: NaturalNews.com - April 6, 2021 Category: Consumer Health News Source Type: news

Mayo Clinic Q & amp;A podcast: Esophageal cancer is one of the deadliest cancers
Esophageal cancer occurs in the esophagus -- a long, hollow tube that runs from the throat to the stomach -- and can occur anywhere along the esophagus. Men are more likely to develop esophageal cancer than women. While treatable, esophageal cancer is rarely curable. "It's an uncommon cancer," says Dr. Shanda Blackmon, a Mayo Clinic general thoracic surgeon. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 5, 2021 Category: Databases & Libraries Source Type: news

Stomach bloating: Is it gas or a sign of bowel cancer? It depends on the other symptoms
STOMACH bloating can feel tight and uncomfortable, but it might be a warning sign of advanced bowel cancer. How can you be sure it's only a little bit of gas, or if the swelling is due to fluid build-up? (Source: Daily Express - Health)
Source: Daily Express - Health - March 27, 2021 Category: Consumer Health News Source Type: news

Aging cells in abdominal fluid cause increased peritoneal dissemination of gastric cancer
(Kumamoto University) Through an analysis of cell fractions from malignant ascites, cellular senescence of cancer-associated fibroblasts (CAFs) has been found to be important in the progression of gastric cancer peritoneal dissemination foci. This understanding should enable the development of new treatments for peritoneal cancer dissemination by targeting cancer cells at dissemination sites and CAFs in patients with peritoneal dissemination. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2021 Category: Biology Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Variations in a gene and a protein aggravate the prognosis of one gastric tumor
(Universidad Complutense de Madrid) More than a million people worldwide were diagnosed with stomach cancer in 2018, the fifth most prevalent cancer. The most common gastric tumor is gastric adenocarcinoma, originating in the gastric mucosa. A research team led by the University Complutense of Madrid in Spain has identified 2 biomarkers that help predict the risk of developing the disease, as well as a poorer prognosis: polymorphisms-variations-of the transforming growth factor B1 (TGFB1) gene and the TGFB1 protein. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news

Andecaliximab Disappoints in Advanced Gastric Cancer Andecaliximab Disappoints in Advanced Gastric Cancer
Objective response rates were 50.5% in the ADX arm and 41.1% in the placebo arm, but this did not translate to improved survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Gallbladder cancer symptoms: Dark urine could be a sign of the deadly disease
THE GALLBLADDER is a small organ that aids the stomach in digestion. When a cancerous tumour forms in that area, the symptoms may seem innocuous. However, put together they could signify a deadly disease. (Source: Daily Express - Health)
Source: Daily Express - Health - March 6, 2021 Category: Consumer Health News Source Type: news

Longtime Bay Area cancer biotech snagged by Amgen in $1.9B deal
The Peninsula biotech shed more than half its jobs in recent years but stayed focused on its gastric cancer drug bemarituzumab, which is ready for Phase III clinical trials and could be used to attack a number of other types of cancer. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 5, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Amgen buys longtime cancer biotech in $1.9 billion deal
The Peninsula biotech shed more than half its jobs in recent years but stayed focused on its gastric cancer drug bemarituzumab, which is ready for Phase III clinical trials and could be used to attack a number of other types of cancer. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Stomach bloating: ‘Sudden’ bloating could signal a deadly disease - what is it?
STOMACH bloating is often a natural response to eating gassy foods but it can signal something serious is up. If you experience sudden bloating, it could signal cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - March 1, 2021 Category: Consumer Health News Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Prostate cancer: Stomach pain, constipation or blood in stools are signs not to ignore
PROSTATE cancer is the most common cancer in men in the UK, with around 40,000 men diagnosed with prostate cancer every year in England alone. Symptoms can take years to surface and when the cancer has advanced there are three warning signs you should not ignore. (Source: Daily Express - Health)
Source: Daily Express - Health - February 12, 2021 Category: Consumer Health News Source Type: news

Bowel cancer: Tenesmus - a sensation when using the toilet - is a warning sign
BOWEL cancer symptoms include weight loss, stomach pain, and feeling very tired for no obvious reason. But you could also be at risk of the disease if you notice small changes to your daily toilet routine, in particular a certain sensation. (Source: Daily Express - Health)
Source: Daily Express - Health - February 10, 2021 Category: Consumer Health News Source Type: news

An Atypical Presentation of Multiple Primary Malignancies An Atypical Presentation of Multiple Primary Malignancies
Gastric carcinoma is the neoplasm most commonly associated with second primary neoplasms. This case underscores the need to consider multiple primary malignancy in patients with gastric cancer.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

A novel approach to determine how carcinogenic bacteria find their targets
(Texas A&M University) The gram-negative bacteria Helicobacter pylori (H. pylori) colonize the stomachs of the majority of the world's population. Although most people may never experience major complications due to the pathogen, H. pylori infections increase the risk of certain types of gastric cancer, as well as other illnesses such as peptic ulcers and gastritis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2021 Category: Cancer & Oncology Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Elderly esophageal cancer patients often receive suboptimal therapy due to perceived risks
(American College of Surgeons) Elderly patients (70 years and over) with locally advanced esophageal (E) and esophagogastric junction (EGJ) cancer (located in the stomach and esophagus) should be considered for optimal therapy that has the potential to cure. This therapy regimen includes initial chemoradiotherapy (NACR) and surgical resection, an operation that removes the cancerous part of the organ. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 9, 2021 Category: Cancer & Oncology Source Type: news

Bowel cancer symptoms: Stomach pain could be indicative of the disease
BOWEL cancer begins in either the colon or rectum, both of which are part of the large bowel. As abnormal cells divide and grow in an uncontrollable manner, signs of the disease start to manifest. (Source: Daily Express - Health)
Source: Daily Express - Health - February 6, 2021 Category: Consumer Health News Source Type: news

Stomach bloating: When is bloating a sign of bowel cancer? What you need to know
BLOATING in the stomach is usually attributed to eating too many gassy foods but it can be a sign of advanced bowel. There are a number of telltale signs that can signal your stomach bloating is a sign of bowel cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - February 2, 2021 Category: Consumer Health News Source Type: news

Can Teenagers Get Stomach Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news

Bemarituzumab FIGHTs Gastric/GEJ Cancers, Improving Survival Bemarituzumab FIGHTs Gastric/GEJ Cancers, Improving Survival
Adding bemarituzumab to chemotherapy as first-line treatment for advanced gastric and gastroesophageal junction (GEJ) cancers improved survival over chemotherapy alone in the phase 2 FIGHT trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 19, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news